Randall Schatzman
Corporate Officer/Principal presso AlderBio Holdings LLC
Patrimonio netto: 7 842 $ in data 31/05/2024
Profilo
Randall C.
Schatzman is the founder.
He founded Lundbeck Seattle BioPharmaceuticals, Inc. in 2004 and served as the President, Chief Executive Officer & Director from 2013 to 2018.
Currently, he is a Manager at AlderBio Holdings LLC.
In his former positions, he was the Chief Executive Officer & Director at Bolt Biotherapeutics, Inc. from 2019 to 2024, the Director-Gene Discovery at Mercator Genetics, Inc. from 1995 to 1999, a Director at Vitaeris, Inc., and the Senior Vice President-Discovery Research at Celltech R&D, Inc. He also held a position as a Principal at Syntex, Inc. Dr. Schatzman holds a doctorate degree from Emory University and an undergraduate degree from Purdue University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 28/03/2024 | 10 359 ( 0.03% ) | 7 842 $ | 31/05/2024 |
Posizioni attive di Randall Schatzman
| Società | Posizione | Inizio |
|---|---|---|
| AlderBio Holdings LLC | Corporate Officer/Principal | - |
Precedenti posizioni note di Randall Schatzman
| Società | Posizione | Fine |
|---|---|---|
| BOLT BIOTHERAPEUTICS, INC. | Amministratore Delegato | 15/05/2024 |
| ALDER BIOPHARMACEUTICALS, INC. | Fondatore | 20/03/2018 |
Mercator Genetics, Inc.
 Mercator Genetics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Progenitor, Inc., Mercator Genetics, Inc. develops gene therapy programs for asthma, schizophrenia, and cancer. The company is based in Menlo Park, CA. Mercator Genetics was acquired by Progenitor, Inc. on February 18, 1997 for $22 million. | Corporate Officer/Principal | 01/01/1999 |
Vitaeris, Inc.
 Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Direttore/Membro del Consiglio | - |
| Syntex, Inc. | Corporate Officer/Principal | - |
Formazione di Randall Schatzman
| Emory University | Doctorate Degree |
| Purdue University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BOLT BIOTHERAPEUTICS, INC. | Health Technology |
| Aziende private | 6 |
|---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Celltech R&D, Inc.
 Celltech R&D, Inc. Drugstore ChainsRetail Trade Celltech R&D, Inc. provides research and development services for pharmaceutical products. The private company is based in Bothell, WA. | Retail Trade |
Mercator Genetics, Inc.
Mercator Genetics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Progenitor, Inc., Mercator Genetics, Inc. develops gene therapy programs for asthma, schizophrenia, and cancer. The company is based in Menlo Park, CA. Mercator Genetics was acquired by Progenitor, Inc. on February 18, 1997 for $22 million. | Commercial Services |
| Syntex, Inc. | Miscellaneous |
| AlderBio Holdings LLC | |
Vitaeris, Inc.
Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Health Technology |
- Borsa valori
- Insiders
- Randall Schatzman
